Treatment with anti-TNF agents is extremely effective in IBD patients, stimulating a regulatory phenotype in macrophages: accordingly, infliximab administration induces CD68+ CD206+ regulatory macrophages [67]. Here, MRC1 is linked to inflammatory bowel disease.